Direkt zum Inhalt

Magnus, Clara Luzia ; Hiergeist, Andreas ; Schuster, Philipp ; Rohrhofer, Anette ; Medenbach, Jan ; Gessner, André ; Peterhoff, David ; Schmidt, Barbara

Targeted escape of SARS-CoV-2 in vitro from monoclonal antibody S309, the precursor of sotrovimab

Magnus, Clara Luzia, Hiergeist, Andreas, Schuster, Philipp, Rohrhofer, Anette, Medenbach, Jan , Gessner, André, Peterhoff, David und Schmidt, Barbara (2022) Targeted escape of SARS-CoV-2 in vitro from monoclonal antibody S309, the precursor of sotrovimab. Frontiers in Immunology 13, S. 966236.

Veröffentlichungsdatum dieses Volltextes: 09 Sep 2022 13:06
Artikel
DOI zum Zitieren dieses Dokuments: 10.5283/epub.52817


Zusammenfassung

Class 1 and 2 monoclonal antibodies inhibit SARS-CoV-2 entry by blocking the interaction of the viral receptor-binding domain with angiotensin-converting enzyme 2 (ACE2), while class 3 antibodies target a highly conserved epitope outside the ACE2 binding site. We aimed to investigate the plasticity of the spike protein by propagating wild-type SARS-CoV-2 in the presence of class 3 antibody S309. ...

Class 1 and 2 monoclonal antibodies inhibit SARS-CoV-2 entry by blocking the interaction of the viral receptor-binding domain with angiotensin-converting enzyme 2 (ACE2), while class 3 antibodies target a highly conserved epitope outside the ACE2 binding site. We aimed to investigate the plasticity of the spike protein by propagating wild-type SARS-CoV-2 in the presence of class 3 antibody S309. After 12 weeks, we obtained a viral strain that was completely resistant to inhibition by S309, due to successively evolving amino acid exchanges R346S and P337L located in the paratope of S309. The antibody lost affinity to receptor-binding domains carrying P337L or both amino acid exchanges, while ACE2 binding was not affected. The resistant strain replicated efficiently in human CaCo-2 cells and was more susceptible to inhibition of fusion than the original strain. Overall, SARS-CoV-2 escaped inhibition by class 3 antibody S309 through a slow, but targeted evolution enabling immune escape and altering cell entry. This immune-driven enhancement of infectivity and pathogenicity could play an important role in the future evolution of SARS-CoV-2, which is under increasing immunological pressure from vaccination and previous infections.



Beteiligte Einrichtungen


Details

DokumentenartArtikel
Titel eines Journals oder einer ZeitschriftFrontiers in Immunology
Verlag:Frontiers
Ort der Veröffentlichung:LAUSANNE
Band:13
Seitenbereich:S. 966236
Datum24 August 2022
InstitutionenMedizin > Lehrstuhl für Medizinische Mikrobiologie und Hygiene
Biologie und Vorklinische Medizin > Institut für Biochemie, Genetik und Mikrobiologie > Lehrstuhl für Biochemie I
Identifikationsnummer
WertTyp
10.3389/fimmu.2022.966236DOI
Stichwörter / Keywords; SARS-CoV-2; receptor-binding domain; monoclonal antibody; sotrovimab; immune escape; entry; endocytosis; fusion
Dewey-Dezimal-Klassifikation500 Naturwissenschaften und Mathematik > 570 Biowissenschaften, Biologie
600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin
StatusVeröffentlicht
BegutachtetJa, diese Version wurde begutachtet
An der Universität Regensburg entstandenJa
URN der UB Regensburgurn:nbn:de:bvb:355-epub-528179
Dokumenten-ID52817

Bibliographische Daten exportieren

Nur für Besitzer und Autoren: Kontrollseite des Eintrags

nach oben